CD147 in Cardiovascular Disease and Thrombosis

Gabrielle J. Pennings; Leonard Kritharides

doi:10.1055/s-0034-1390001

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2014; 40(07): 747-755
DOI: 10.1055/s-0034-1390001

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

CD147 in Cardiovascular Disease and Thrombosis

Gabrielle J. Pennings

¹Vascular Biology Group, The ANZAC Research Institute, The University of Sydney, Concord Repatriation General Hospital, New South Wales, Australia

,

Leonard Kritharides

²Atherosclerosis and Vascular Biology Groups, The ANZAC Research Institute, The University of Sydney, New South Wales, Australia

³Department of Cardiology, Concord Repatriation General Hospital, New South Wales, Australia

› Author Affiliations

Abstract

Thrombotic and inflammatory pathways play a key role in coronary artery disease (CAD) development. Extracellular matrix metalloproteinase (aka CD147) is a member of the immunoglobulin superfamily that is expressed on many cell types including hematopoietic, endothelial cells, leukocytes, keratinocytes, platelets, and others. The binding partners of CD147 are numerous and diverse, and give some indication to the various roles that CD147 can play; these include homophilic interactions, integrins, cyclophilins, glycoprotein VI (GPVI), caveolin 1, and monocarboxylate transporters. Recent evidence suggests a role for CD147 in both thrombosis and inflammation, as well as involvement in CAD and cancer. In this review, we summarize the role of CD147 and its binding partners in platelets, thrombosis, and arterial disease and assess mechanistic aspects of CD147 biology.

Keywords

CD147 - EMMPRIN - CAD - thrombosis - cyclophilin

Full Text

References

References
1 von Hundelshausen P, Weber C. Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res 2007; 100 (1) 27-40
2 Vorchheimer DA, Becker R. Platelets in atherothrombosis. Mayo Clin Proc 2006; 81 (1) 59-68
3 Garlichs CD, Eskafi S, Raaz D , et al. Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets. Heart 2001; 86 (6) 649-655
4 Pennings GJ, Yong ASC, Kritharides L. Expression of EMMPRIN (CD147) on circulating platelets in vivo. J Thromb Haemost 2010; 8 (3) 472-481
5 Tan KT, Tayebjee MH, Macfadyen RJ, Lip GY, Blann AD. Elevated platelet microparticles in stable coronary artery disease are unrelated to disease severity or to indices of inflammation. Platelets 2005; 16 (6) 368-371
6 Wang J, Zhang S, Jin Y, Qin G, Yu L, Zhang J. Elevated levels of platelet-monocyte aggregates and related circulating biomarkers in patients with acute coronary syndrome. Int J Cardiol 2007; 115 (3) 361-365
7 Inoue T, Kato T, Takayanagi K , et al. Circulating matrix metalloproteinase-1 and -3 in patients with an acute coronary syndrome. Am J Cardiol 2003; 92 (12) 1461-1464
8 Kai H, Ikeda H, Yasukawa H , et al. Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 1998; 32 (2) 368-372
9 Zeng B, Prasan A, Fung KC , et al. Elevated circulating levels of matrix metalloproteinase-9 and -2 in patients with symptomatic coronary artery disease. Intern Med J 2005; 35 (6) 331-335
10 Stockinger H, Ebel T, Hansmann C , et al. EC16 CD147 (neurothelin/basigin) workshop panel report. In: Kishimoto T, Kikutani H, von dem Borne AEGK, , eds. Leukocyte Typing VI: White Cell Differentiation Antigens. New York, NY: Garland Publishing Inc; 1998: 760-763
11 Biswas C. Tumor cell stimulation of collagenase production by fibroblasts. Biochem Biophys Res Commun 1982; 109 (3) 1026-1034
12 Biswas C, Zhang Y, DeCastro R , et al. The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res 1995; 55 (2) 434-439
13 Kataoka H, DeCastro R, Zucker S, Biswas C. Tumor cell-derived collagenase-stimulatory factor increases expression of interstitial collagenase, stromelysin, and 72-kDa gelatinase. Cancer Res 1993; 53 (13) 3154-3158
14 Prescott J, Troccoli N, Biswas C. Coordinate increase in collagenase mRNA and enzyme levels in human fibroblasts treated with the tumor cell factor, TCSF. Biochem Int 1989; 19 (2) 257-266
15 Miyauchi T, Masuzawa Y, Muramatsu T. The basigin group of the immunoglobulin superfamily: complete conservation of a segment in and around transmembrane domains of human and mouse basigin and chicken HT7 antigen. J Biochem 1991; 110 (5) 770-774
16 Kasinrerk W, Fiebiger E, Stefanová I, Baumruker T, Knapp W, Stockinger H. Human leukocyte activation antigen M6, a member of the Ig superfamily, is the species homologue of rat OX-47, mouse basigin, and chicken HT7 molecule. J Immunol 1992; 149 (3) 847-854
17 DeCastro R, Zhang Y, Guo H , et al. Human keratinocytes express EMMPRIN, an extracellular matrix metalloproteinase inducer. J Invest Dermatol 1996; 106 (6) 1260-1265
18 Schmidt R, Bültmann A, Fischel S , et al. Extracellular matrix metalloproteinase inducer (CD147) is a novel receptor on platelets, activates platelets, and augments nuclear factor kappaB-dependent inflammation in monocytes. Circ Res 2008; 102 (3) 302-309
19 Iacono KT, Brown AL, Greene MI, Saouaf SJ. CD147 immunoglobulin superfamily receptor function and role in pathology. Exp Mol Pathol 2007; 83 (3) 283-295
20 Muramatsu T, Miyauchi T. Basigin (CD147): a multifunctional transmembrane protein involved in reproduction, neural function, inflammation and tumor invasion. Histol Histopathol 2003; 18 (3) 981-987
21 Bai Y, Huang W, Ma LT, Jiang JL, Chen ZN. Importance of N-glycosylation on CD147 for its biological functions. Int J Mol Sci 2014; 15 (4) 6356-6377
22 Taylor PM, Woodfield RJ, Hodgkin MN , et al. Breast cancer cell-derived EMMPRIN stimulates fibroblast MMP2 release through a phospholipase A(2) and 5-lipoxygenase catalyzed pathway. Oncogene 2002; 21 (37) 5765-5772
23 Gabison EE, Hoang-Xuan T, Mauviel A, Menashi S. EMMPRIN/CD147, an MMP modulator in cancer, development and tissue repair. Biochimie 2005; 87 (3-4) 361-368
24 Huet E, Gabison EE, Mourah S, Menashi S. Role of emmprin/CD147 in tissue remodeling. Connect Tissue Res 2008; 49 (3) 175-179
25 Weidle UH, Scheuer W, Eggle D, Klostermann S, Stockinger H. Cancer-related issues of CD147. Cancer Genomics Proteomics 2010; 7 (3) 157-169
26 Schmidt R, Bültmann A, Ungerer M , et al. Extracellular matrix metalloproteinase inducer regulates matrix metalloproteinase activity in cardiovascular cells: implications in acute myocardial infarction. Circulation 2006; 113 (6) 834-841
27 Yong A, Pennings G, Wong C , et al. Intracoronary upregulation of platelet extracellular matrix metalloproteinase inducer (CD147) in coronary disease. Int J Cardiol 2013; 166 (3) 716-721
28 Major TC, Liang L, Lu X, Rosebury W, Bocan TM. Extracellular matrix metalloproteinase inducer (EMMPRIN) is induced upon monocyte differentiation and is expressed in human atheroma. Arterioscler Thromb Vasc Biol 2002; 22 (7) 1200-1207
29 Arora K, Gwinn WM, Bower MA , et al. Extracellular cyclophilins contribute to the regulation of inflammatory responses. J Immunol 2005; 175 (1) 517-522
30 Gwinn WM, Damsker JM, Falahati R , et al. Novel approach to inhibit asthma-mediated lung inflammation using anti-CD147 intervention. J Immunol 2006; 177 (7) 4870-4879
31 Tian X, Zhao C, Zhu H , et al. Hepatitis B virus (HBV) surface antigen interacts with and promotes cyclophilin a secretion: possible link to pathogenesis of HBV infection. J Virol 2010; 84 (7) 3373-3381
32 Agrawal SM, Silva C, Tourtellotte WW, Yong VW. EMMPRIN: a novel regulator of leukocyte transmigration into the CNS in multiple sclerosis and experimental autoimmune encephalomyelitis. J Neurosci 2011; 31 (2) 669-677
33 Wang P, Heitman J. The cyclophilins. Genome Biol 2005; 6 (7) 226
34 Pushkarsky T, Zybarth G, Dubrovsky L , et al. CD147 facilitates HIV-1 infection by interacting with virus-associated cyclophilin A. Proc Natl Acad Sci U S A 2001; 98 (11) 6360-6365
35 Yurchenko V, O'Connor M, Dai WW , et al. CD147 is a signaling receptor for cyclophilin B. Biochem Biophys Res Commun 2001; 288 (4) 786-788
36 Yurchenko V, Zybarth G, O'Connor M , et al. Active site residues of cyclophilin A are crucial for its signaling activity via CD147. J Biol Chem 2002; 277 (25) 22959-22965
37 Yurchenko V, Pushkarsky T, Li JH, Dai WW, Sherry B, Bukrinsky M. Regulation of CD147 cell surface expression: involvement of the proline residue in the CD147 transmembrane domain. J Biol Chem 2005; 280 (17) 17013-17019
38 Satoh K, Fukumoto Y, Sugimura K , et al. Plasma cyclophilin A is a novel biomarker for coronary artery disease. Circ J 2013; 77 (2) 447-455
39 Seizer P, Schönberger T, Schött M , et al. EMMPRIN and its ligand cyclophilin A regulate MT1-MMP, MMP-9 and M-CSF during foam cell formation. Atherosclerosis 2010; 209 (1) 51-57
40 Sluijter JP, Pulskens WP, Schoneveld AH , et al. Matrix metalloproteinase 2 is associated with stable and matrix metalloproteinases 8 and 9 with vulnerable carotid atherosclerotic lesions: a study in human endarterectomy specimen pointing to a role for different extracellular matrix metalloproteinase inducer glycosylation forms. Stroke 2006; 37 (1) 235-239
41 Nigro P, Satoh K, O'Dell MR , et al. Cyclophilin A is an inflammatory mediator that promotes atherosclerosis in apolipoprotein E-deficient mice. J Exp Med 2011; 208 (1) 53-66
42 Seizer P, Gawaz M, May AE. Cyclophilin A and EMMPRIN (CD147) in cardiovascular diseases. Cardiovasc Res 2014; 102 (1) 17-23
43 Elvers M, Herrmann A, Seizer P , et al. Intracellular cyclophilin A is an important Ca(2+) regulator in platelets and critically involved in arterial thrombus formation. Blood 2012; 120 (6) 1317-1326
44 Wang L, Soe NN, Sowden M , et al. Cyclophilin A is an important mediator of platelet function by regulating integrin αIIbβ3 bidirectional signalling. Thromb Haemost 2014; 111 (5) 873-882
45 Hagemeyer CE, Peter K. Targeting the platelet integrin GPIIb/IIIa. Curr Pharm Des 2010; 16 (37) 4119-4133
46 Seizer P, Ochmann C, Schönberger T , et al. Disrupting the EMMPRIN (CD147)-cyclophilin A interaction reduces infarct size and preserves systolic function after myocardial ischemia and reperfusion. Arterioscler Thromb Vasc Biol 2011; 31 (6) 1377-1386
47 Yoon YW, Kwon HM, Hwang KC , et al. Upstream regulation of matrix metalloproteinase by EMMPRIN; extracellular matrix metalloproteinase inducer in advanced atherosclerotic plaque. Atherosclerosis 2005; 180 (1) 37-44
48 Sun J, Hemler ME. Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metalloproteinase inducer interactions. Cancer Res 2001; 61 (5) 2276-2281
49 Gawaz M. The evolving science of atherothrombotic disease. Eur Heart J Suppl 2008; 10 (suppl I ): I4-I7
50 Pennings GJ, Yong AS, Wong C , et al. Circulating levels of soluble EMMPRIN (CD147) correlate with levels of soluble glycoprotein VI in human plasma. Platelets 2013;
51 Al-Tamimi M, Tan CW, Qiao J , et al. Pathologic shear triggers shedding of vascular receptors: a novel mechanism for down-regulation of platelet glycoprotein VI in stenosed coronary vessels. Blood 2012; 119 (18) 4311-4320
52 Al-Tamimi M, Mu FT, Moroi M, Gardiner EE, Berndt MC, Andrews RK. Measuring soluble platelet glycoprotein VI in human plasma by ELISA. Platelets 2009; 20 (3) 143-149
53 Seizer P, Borst O, Langer HF , et al. EMMPRIN (CD147) is a novel receptor for platelet GPVI and mediates platelet rolling via GPVI-EMMPRIN interaction. Thromb Haemost 2009; 101 (4) 682-686
54 Quemener C, Gabison EE, Naïmi B , et al. Extracellular matrix metalloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion. Cancer Res 2007; 67 (1) 9-15
55 Ulisse S, Baldini E, Sorrenti S, D'Armiento M. The urokinase plasminogen activator system: a target for anti-cancer therapy. Curr Cancer Drug Targets 2009; 9 (1) 32-71
56 Mehta R, Shapiro AD. Plasminogen activator inhibitor type 1 deficiency. Haemophilia 2008; 14 (6) 1255-1260
57 Farris SD, Hu JH, Krishnan R , et al. Mechanisms of urokinase plasminogen activator (uPA)-mediated atherosclerosis: role of the uPA receptor and S100A8/A9 proteins. J Biol Chem 2011; 286 (25) 22665-22677
58 Binder BR, Mihaly J, Prager GW. uPAR-uPA-PAI-1 interactions and signaling: a vascular biologist's view. Thromb Haemost 2007; 97 (3) 336-342
59 Robbie LA, Booth NA, Brown AJ, Bennett B. Inhibitors of fibrinolysis are elevated in atherosclerotic plaque. Arterioscler Thromb Vasc Biol 1996; 16 (4) 539-545
60 Reddel CJ, Curnow JL, Voitl J , et al. Detection of hypofibrinolysis in stable coronary artery disease using the overall haemostatic potential assay. Thromb Res 2013; 131 (5) 457-462
61 Lescaille G, Menashi S, Cavelier-Balloy B , et al. EMMPRIN/CD147 up-regulates urokinase-type plasminogen activator: implications in oral tumor progression. BMC Cancer 2012; 12: 115
62 Montero L, Nagamine Y. Regulation by p38 mitogen-activated protein kinase of adenylate- and uridylate-rich element-mediated urokinase-type plasminogen activator (uPA) messenger RNA stability and uPA-dependent in vitro cell invasion. Cancer Res 1999; 59 (20) 5286-5293
63 Halestrap AP, Price NT. The proton-linked monocarboxylate transporter (MCT) family: structure, function and regulation. Biochem J 1999; 343 (Pt 2) 281-299
64 Deora AA, Philp N, Hu J, Bok D, Rodriguez-Boulan E. Mechanisms regulating tissue-specific polarity of monocarboxylate transporters and their chaperone CD147 in kidney and retinal epithelia. Proc Natl Acad Sci U S A 2005; 102 (45) 16245-16250
65 Merezhinskaya N, Ogunwuyi SA, Fishbein WN. Expression of monocarboxylate transporter 4 in human platelets, leukocytes, and tissues assessed by antibodies raised against terminal versus pre-terminal peptides. Mol Genet Metab 2006; 87 (2) 152-161
66 Xu D, Hemler ME. Metabolic activation-related CD147-CD98 complex. Mol Cell Proteomics 2005; 4 (8) 1061-1071
67 Hosoya K, Kondo T, Tomi M, Takanaga H, Ohtsuki S, Terasaki T. MCT1-mediated transport of L-lactic acid at the inner blood-retinal barrier: a possible route for delivery of monocarboxylic acid drugs to the retina. Pharm Res 2001; 18 (12) 1669-1676
68 Utoguchi N, Audus KL. Carrier-mediated transport of valproic acid in BeWo cells, a human trophoblast cell line. Int J Pharm 2000; 195 (1-2) 115-124
69 Wu X, Whitfield LR, Stewart BH. Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter. Pharm Res 2000; 17 (2) 209-215
70 Gallagher SM, Castorino JJ, Wang D, Philp NJ. Monocarboxylate transporter 4 regulates maturation and trafficking of CD147 to the plasma membrane in the metastatic breast cancer cell line MDA-MB-231. Cancer Res 2007; 67 (9) 4182-4189
71 Jia L, Wang S, Zhou H, Cao J, Hu Y, Zhang J. Caveolin-1 up-regulates CD147 glycosylation and the invasive capability of murine hepatocarcinoma cell lines. Int J Biochem Cell Biol 2006; 38 (9) 1584-1593
72 Tang W, Hemler ME. Caveolin-1 regulates matrix metalloproteinases-1 induction and CD147/EMMPRIN cell surface clustering. J Biol Chem 2004; 279 (12) 11112-11118
73 Liu P, Rudick M, Anderson RG. Multiple functions of caveolin-1. J Biol Chem 2002; 277 (44) 41295-41298
74 Tang W, Chang SB, Hemler ME. Links between CD147 function, glycosylation, and caveolin-1. Mol Biol Cell 2004; 15 (9) 4043-4050
75 Jayachandran M, Miller VM. Human platelets contain estrogen receptor α, caveolin-1 and estrogen receptor associated proteins. Platelets 2003; 14 (2) 75-81
76 Berditchevski F, Chang S, Bodorova J, Hemler ME. Generation of monoclonal antibodies to integrin-associated proteins. Evidence that alpha3beta1 complexes with EMMPRIN/basigin/OX47/M6. J Biol Chem 1997; 272 (46) 29174-29180
77 Cho JY, Fox DA, Horejsi V , et al. The functional interactions between CD98, beta1-integrins, and CD147 in the induction of U937 homotypic aggregation. Blood 2001; 98 (2) 374-382
78 Tang J, Wu YM, Zhao P, Yang XM, Jiang JL, Chen ZN. Overexpression of HAb18G/CD147 promotes invasion and metastasis via alpha3beta1 integrin mediated FAK-paxillin and FAK-PI3K-Ca2+ pathways. Cell Mol Life Sci 2008; 65 (18) 2933-2942
79 Dai JY, Dou KF, Wang CH , et al. The interaction of HAb18G/CD147 with integrin alpha6beta1 and its implications for the invasion potential of human hepatoma cells. BMC Cancer 2009; 9: 337
80 Sonnenberg A, Modderman PW, Hogervorst F. Laminin receptor on platelets is the integrin VLA-6. Nature 1988; 336 (6198) 487-489
81 Rauch U, Saxena A, Lorkowski S , et al. Laminin isoforms in atherosclerotic arteries from mice and man. Histol Histopathol 2011; 26 (6) 711-724
82 Papadimitropoulou A, Mamalaki A. The glycosylated IgII extracellular domain of EMMPRIN is implicated in the induction of MMP-2. Mol Cell Biochem 2013; 379 (1-2) 107-113
83 Kirk P, Wilson MC, Heddle C, Brown MH, Barclay AN, Halestrap AP. CD147 is tightly associated with lactate transporters MCT1 and MCT4 and facilitates their cell surface expression. EMBO J 2000; 19 (15) 3896-3904
84 Belton Jr RJ, Chen L, Mesquita FS, Nowak RA. Basigin-2 is a cell surface receptor for soluble basigin ligand. J Biol Chem 2008; 283 (26) 17805-17814
85 Bao W, Min D, Twigg SM , et al. Monocyte CD147 is induced by advanced glycation end products and high glucose concentration: possible role in diabetic complications. Am J Physiol Cell Physiol 2010; 299 (5) C1212-C1219
86 Egawa N, Koshikawa N, Tomari T, Nabeshima K, Isobe T, Seiki M. Membrane type 1 matrix metalloproteinase (MT1-MMP/MMP-14) cleaves and releases a 22-kDa extracellular matrix metalloproteinase inducer (EMMPRIN) fragment from tumor cells. J Biol Chem 2006; 281 (49) 37576-37585
87 Sidhu SS, Mengistab AT, Tauscher AN, LaVail J, Basbaum C. The microvesicle as a vehicle for EMMPRIN in tumor-stromal interactions. Oncogene 2004; 23 (4) 956-963
88 Kazes I, Elalamy I, Sraer JD, Hatmi M, Nguyen G. Platelet release of trimolecular complex components MT1-MMP/TIMP2/MMP2: involvement in MMP2 activation and platelet aggregation. Blood 2000; 96 (9) 3064-3069
89 Amit-Cohen BC, Rahat MM, Rahat MA. Tumor cell-macrophage interactions increase angiogenesis through secretion of EMMPRIN. Front Physiol 2013; 4: 178
90 Biswas C. Collagenase stimulation in cocultures of human fibroblasts and human tumor cells. Cancer Lett 1984; 24 (2) 201-207
91 Biswas C, Nugent MA. Membrane association of collagenase stimulatory factor(s) from B-16 melanoma cells. J Cell Biochem 1987; 35 (3) 247-258
92 Ellis SM, Nabeshima K, Biswas C. Monoclonal antibody preparation and purification of a tumor cell collagenase-stimulatory factor. Cancer Res 1989; 49 (12) 3385-3391
93 Altruda F, Cervella P, Gaeta ML , et al. Cloning of cDNA for a novel mouse membrane glycoprotein (gp42): shared identity to histocompatibility antigens, immunoglobulins and neural-cell adhesion molecules. Gene 1989; 85 (2) 445-451
94 Miyauchi T, Kanekura T, Yamaoka A, Ozawa M, Miyazawa S, Muramatsu T. Basigin, a new, broadly distributed member of the immunoglobulin superfamily, has strong homology with both the immunoglobulin V domain and the beta-chain of major histocompatibility complex class II antigen. J Biochem 1990; 107 (2) 316-323
95 Nabeshima K, Lane WS, Biswas C. Partial sequencing and characterization of the tumor cell-derived collagenase stimulatory factor. Arch Biochem Biophys 1991; 285 (1) 90-96
96 Nabeshima K, Iwasaki H, Koga K, Hojo H, Suzumiya J, Kikuchi M. Emmprin (basigin/CD147): matrix metalloproteinase modulator and multifunctional cell recognition molecule that plays a critical role in cancer progression. Pathol Int 2006; 56 (7) 359-367
97 Zhu X, Song Z, Zhang S, Nanda A, Li G. CD147: a novel modulator of inflammatory and immune disorders. Curr Med Chem 2014; 21 (19) 2138-2145